Stage IV (D)/Relapsed Colon Cancer


Erbitux Plus FOLFIRI Outperforms Avastin Plus FOLFIRI for First-Line Treatment of Metastatic Colorectal Cancer (06-20-2013)

For the initial (first-line) treatment of metastatic colorectal cancer with no KRAS gene mutations, the combination of Erbitux® (cetuximab) and FOLFIRI chemotherapy was more effective than the combination of Avastin® (bevacizumab) and FOLFIRI. These... Continue Reading

KRAS Affects Outcomes with Erbitux® in Colorectal Cancer (10-27-2008)

KRAS Affects Outcomes with Erbitux® in Colorectal Cancer The KRAS mutation affects survival among patients with colorectal cancer who are treated with Erbitux (cetuximab). These results were recently published in the New England Journal of Medicine. Colorectal... Continue Reading